Introducing NICE’s new board members
European Pharmaceutical Review explores who will be joining the National Institute of Health and Care Excellence (NICE)’s board as a new non-executive director on 1 April 2021.
List view / Grid view
European Pharmaceutical Review explores who will be joining the National Institute of Health and Care Excellence (NICE)’s board as a new non-executive director on 1 April 2021.
According to Regeneron, it has placed either first or second in the same ranking for the past ten years, making it the most highly ranked company of the decade.
Researchers suggest, based on certain exclusions, older people are likely to be underrepresented in 50 percent of COVID-19 trials and all vaccine trials in the US.
Pharma executives are committed to bringing drugs to market to improve the lives of patients but is the industry too introspective to be truly innovative?
Professor Gillian Leng has been appointed as the new Chief Executive of NICE and will take over from Sir Andrew Dillon in early April.
New research has revealed that despite a rising number of women in STEM publishing papers, there is a large gender difference due to females leaving academia.
A survey by the Internal Investigations Forum has highlighted vast differences in the quantity and quality of complaint reports globally and that companies need to nurture trust to improve internal relations. Here, Gary Giampetruzzi, Thomas Hauser and Jenny Pu provide an analysis of the results, including where there are areas…
The ABPI has outlined how the new immigration system in the UK will affect life science workers and businesses, emphasising the need for regular reviews to remain competitive.
Boris Johnson, the Prime Minister of the UK, has announced a new Global Talent visa for researchers and scientists which will fast track those in certain fields.
Dr Stephen Hahn has been voted into the role of FDA commissioner by the US Senate, taking over the role from Ned Sharpless.
The ABPI’s board has unanimously appointed Dr Richard Torbett as Chief Executive, commencing 1 January 2020.
ABPI Chief Executive, Mike Thompson, will retire at the end of 2019.
Haseeb Ahmad from Novartis Pharmaceuticals has been confirmed as the new president of the The Association of the British Pharmaceutical Industry (ABPI).
Coulter Partners has placed Dr Neil Brewis as Chief Scientific Officer and Michael Davies as VP Protein Science at F-star, a leading biopharmaceutical company developing novel bispecific antibodies with a focus on immuno-oncology.
CEVEC Pharmaceuticals, the developer and licensor of the CAP Technology, today announced its new management team.